Merck's $500M bet on Singapore leads to new manufacturing sites making Keytruda, Gardasil and future inhalers

In a boost to its Asia Pacific regional headquarters in Singapore, Merck has opened a new secondary packaging facility and broken ground on a separate facility that will manufacture next-generation inhalers.

The two manufacturing sites are part of a $500 million investment to expand production of medicines and vaccines in Singapore over five years, dating back to 2020.